QYUNS-B Receives Milestone Payment from Roche Following First Patient Dosing in Phase I Trial for QX031N

Stock News05-27

QYUNS-B (02509) announced that it received a milestone payment from its partner F. Hoffmann-La Roche Ltd (referred to as "Roche") on May 27, 2026. The payment was triggered upon the completion of the first patient dosing in the Phase I clinical trial for the QX031N project (Roche R&D code: RG6981).

QX031N has commenced a Phase I, first-in-human, randomized, double-blind, placebo-controlled, single and multiple ascending dose, parallel-group study in New Zealand. The study aims to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of QX031N in healthy subjects as well as subjects with chronic obstructive pulmonary disease (COPD) and asthma. The first patient in this study was dosed on March 27, 2026.

On October 28, 2025, the company entered into a global exclusive collaboration and license agreement with Roche, granting Roche exclusive worldwide rights to develop, manufacture, and commercialize QX031N.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1162349960?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-27 21:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1162349960","market":"other","top_or_hot":-1,"title":"QYUNS-B Receives Milestone Payment from Roche Following First Patient Dosing in Phase I Trial for QX031N","media":"Stock News","content":"<p>QYUNS-B (02509) announced that it received a milestone payment from its partner F. Hoffmann-La Roche Ltd (referred to as \"Roche\") on May 27, 2026. The payment was triggered upon the completion of the first patient dosing in the Phase I clinical trial for the QX031N project (Roche R&D code: RG6981).</p>\n<p>QX031N has commenced a Phase I, first-in-human, randomized, double-blind, placebo-controlled, single and multiple ascending dose, parallel-group study in New Zealand. The study aims to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of QX031N in healthy subjects as well as subjects with chronic obstructive pulmonary disease (COPD) and asthma. The first patient in this study was dosed on March 27, 2026.</p>\n<p>On October 28, 2025, the company entered into a global exclusive collaboration and license agreement with Roche, granting Roche exclusive worldwide rights to develop, manufacture, and commercialize QX031N.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>QYUNS-B Receives Milestone Payment from Roche Following First Patient Dosing in Phase I Trial for QX031N</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nQYUNS-B Receives Milestone Payment from Roche Following First Patient Dosing in Phase I Trial for QX031N\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-05-27 21:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>QYUNS-B (02509) announced that it received a milestone payment from its partner F. Hoffmann-La Roche Ltd (referred to as \"Roche\") on May 27, 2026. The payment was triggered upon the completion of the first patient dosing in the Phase I clinical trial for the QX031N project (Roche R&D code: RG6981).</p>\n<p>QX031N has commenced a Phase I, first-in-human, randomized, double-blind, placebo-controlled, single and multiple ascending dose, parallel-group study in New Zealand. The study aims to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of QX031N in healthy subjects as well as subjects with chronic obstructive pulmonary disease (COPD) and asthma. The first patient in this study was dosed on March 27, 2026.</p>\n<p>On October 28, 2025, the company entered into a global exclusive collaboration and license agreement with Roche, granting Roche exclusive worldwide rights to develop, manufacture, and commercialize QX031N.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02509","symbol_name":"荃信生物-B","start_time":0,"source_url":"","article_id":"1162349960","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1162349960","pubTimestamp":1779886961,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"QYUNS-B (02509) announced that it received a milestone payment from its partner F. Hoffmann-La Roche Ltd (referred to as \"Roche\") on May 27, 2026. The payment was triggered upon the completion of the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02509":"荃信生物-B","BK1161":"生物科技"},"translate_title":"QYUNS-B在QX031N I期试验中首次患者给药后收到罗氏的里程碑付款","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02509":1},"content_text":"QYUNS-B (02509) announced that it received a milestone payment from its partner F. Hoffmann-La Roche Ltd (referred to as \"Roche\") on May 27, 2026. The payment was triggered upon the completion of the first patient dosing in the Phase I clinical trial for the QX031N project (Roche R&D code: RG6981).\nQX031N has commenced a Phase I, first-in-human, randomized, double-blind, placebo-controlled, single and multiple ascending dose, parallel-group study in New Zealand. The study aims to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of QX031N in healthy subjects as well as subjects with chronic obstructive pulmonary disease (COPD) and asthma. The first patient in this study was dosed on March 27, 2026.\nOn October 28, 2025, the company entered into a global exclusive collaboration and license agreement with Roche, granting Roche exclusive worldwide rights to develop, manufacture, and commercialize QX031N.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1162349960","isCrawlerRequest":true}